Optimal drug and behavior therapy for treatment-refractory schizophrenic patients

Robert Paul Liberman, Theodore Van Putten, Barringer D. Marshall, Jim Mintz, Linda Bowen, Timothy G. Kuehnel, Manickan Aravagiri, Stephen R. Marder

Research output: Contribution to journalArticlepeer-review

34 Scopus citations


Thirteen treatment-refractory schizophrenic patients (10 men and three women) who were receiving more than 50 mg/day of haloperidol and who had been hospitalized for more than 1 year successfully tolerated a mean dose reduction of 63% with consequent improvement in psychopathology and side effects. The addition of intensive behavior therapy to the optimal dose of haloperidol yielded further improvements in functional behavior, such as self-care and social interaction.

Original languageEnglish (US)
Pages (from-to)756-759
Number of pages4
JournalAmerican Journal of Psychiatry
Issue number5
StatePublished - May 1994
Externally publishedYes

ASJC Scopus subject areas

  • Psychiatry and Mental health


Dive into the research topics of 'Optimal drug and behavior therapy for treatment-refractory schizophrenic patients'. Together they form a unique fingerprint.

Cite this